These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35585670)

  • 1. Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy.
    Shan S; Chen J; Sun Y; Wang Y; Xia B; Tan H; Pan C; Gu G; Zhong J; Qing G; Zhang Y; Wang J; Wang Y; Wang Y; Zuo P; Xu C; Li F; Guo W; Xu L; Chen M; Fan Y; Zhang L; Liang XJ
    Adv Sci (Weinh); 2022 Jul; 9(21):e2200353. PubMed ID: 35585670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
    Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
    Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
    Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
    Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
    Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
    Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
    Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
    Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
    Fons NR; Sundaram RK; Breuer GA; Peng S; McLean RL; Kalathil AN; Schmidt MS; Carvalho DM; Mackay A; Jones C; Carcaboso ÁM; Nazarian J; Berens ME; Brenner C; Bindra RS
    Nat Commun; 2019 Aug; 10(1):3790. PubMed ID: 31439867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma.
    Arms LM; Duchatel RJ; Jackson ER; Sobrinho PG; Dun MD; Hua S
    J Control Release; 2024 Jun; 370():835-865. PubMed ID: 38744345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
    Monje M; Cooney T; Glod J; Huang J; Peer CJ; Faury D; Baxter P; Kramer K; Lenzen A; Robison NJ; Kilburn L; Vinitsky A; Figg WD; Jabado N; Fouladi M; Fangusaro J; Onar-Thomas A; Dunkel IJ; Warren KE
    Neuro Oncol; 2023 Dec; 25(12):2262-2272. PubMed ID: 37526549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.
    Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ
    PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
    Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
    Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
    Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
    Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery.
    Singleton WGB; Bienemann AS; Woolley M; Johnson D; Lewis O; Wyatt MJ; Damment SJP; Boulter LJ; Killick-Cole CL; Asby DJ; Gill SS
    J Neurosurg Pediatr; 2018 Sep; 22(3):288-296. PubMed ID: 29856296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
    Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
    Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.
    Rodgers LT; Lester McCully CM; Odabas A; Cruz R; Peer CJ; Figg WD; Warren KE
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):827-830. PubMed ID: 31894347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.
    Balakrishnan I; Danis E; Pierce A; Madhavan K; Wang D; Dahl N; Sanford B; Birks DK; Davidson N; Metselaar DS; Meel MH; Lemma R; Donson A; Vijmasi T; Katagi H; Sola I; Fosmire S; Alimova I; Steiner J; Gilani A; Hulleman E; Serkova NJ; Hashizume R; Hawkins C; Carcaboso AM; Gupta N; Monje M; Jabado N; Jones K; Foreman N; Green A; Vibhakar R; Venkataraman S
    Cell Rep; 2020 Oct; 33(3):108286. PubMed ID: 33086074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.
    Weisbrod LJ; Thiraviyam A; Vengoji R; Shonka N; Jain M; Ho W; Batra SK; Salehi A
    Cancer Lett; 2024 May; 590():216876. PubMed ID: 38609002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.